Compare Regeneron Pharmaceuticals Inc (REGN) vs Raytheon Technologies Corp (RTX) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

RTX trades at $197.55, down 1.61% today, but maintains a bullish technical outlook with strong support near $197 and resistance at $200. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.75. Revenue growth accelerated to $88.6 billion in 2025, with net income reaching $6.73 billion. Recent contract wins include a $515 million U.S. Navy radar award announced June 3, 2026.

Outlook remains positive with 65% analyst buy ratings and a $235.33 price target implying 19% upside. Key risks include execution challenges in scaling munitions production and dependence on defense budgets. Strong cash flow generation and expanding margins support continued dividend payments, with the next $0.73 dividend payable September 3, 2026.